Effects of Metformin Plus Gliclazide Compared with Metformin Alone on Circulating Endothelial Progenitor Cell in Type 2 Diabetic Patients

Overview

Journal Endocrine

Specialty Endocrinology

Date 2010 Oct 26

PMID 20972736

Citations 22

Authors

Lu-Lu Chen

Yun-Fei Liao

Tian-Shu Zeng

Fan Yu

Hui-Qing Li

Yong Feng

Affiliations

Soon will be listed here.

Abstract

Circulating endothelial progenitor cells (EPCs) play an important role in the development and progression of diabetic vascular complications. The aim of this study was to investigate the effects of gliclazide plus metformin (GLIMET) compared with metformin alone (MET) on number and function of circulating EPCs in T2DM patients. Patients with newly diagnosed T2DM were randomly divided into two groups, receiving the following treatments for 16 weeks: MET group (assuming metformin 500-2500 mg/day, n=24) and GLIMET group [assuming gliclazide (modified release, 30-60 mg/day)+metformin (250-1000 mg/day), n=23]. Circulating EPCs were quantified by flow cytometry, and the ability to uptake LDL and stain for lectin were used as another method of characterizing EPCs ex vivo. The functions of circulating EPCs were evaluated by colony-forming units (CFU) and migration. The status of oxidative stress was analyzed by serum-free malonaldehyde (MDA) and superoxide dismutase (SOD). There were no significant differences in clinical characteristics and number and function of circulating EPCs between two groups at baseline. Glycemic responses were similar after treatments. Compared with MET group, GLIMET group was associated with an increase in circulating EPCs number, DiLDL-lectin-positive EPCs, and migration. The mean improvements in MDA and SOD of GLIMET group were more strongly upregulated than those of MET group. This study demonstrated that both metformin mono-treatment and metformin plus gliclazide combination treatment provided with improvements in number and function of circulating EPCs. Compared with metformin mono-treatment, early use of combination therapy with gliclazide plus metformin made more effective improvements in circulating EPCs.

Citing Articles

The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease.

Hershenson R, Nardi-Agmon I, Leshem-Lev D, Kornowski R, Eisen A Cardiovasc Diabetol. 2024; 23(1):386.

PMID: 39468546 PMC: 11520434. DOI: 10.1186/s12933-024-02466-x.

The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells.

Altabas V, Marinkovic Radosevic J, Spoljarec L, Uremovic S, Bulum T Biomedicines. 2023; 11(11).

PMID: 38002051 PMC: 10669792. DOI: 10.3390/biomedicines11113051.

Endothelial progenitor cells as biomarkers of diabetes-related cardiovascular complications.

Benitez-Camacho J, Ballesteros A, Beltran-Camacho L, Rojas-Torres M, Rosal-Vela A, Jimenez-Palomares M Stem Cell Res Ther. 2023; 14(1):324.

PMID: 37950274 PMC: 10636846. DOI: 10.1186/s13287-023-03537-8.

Repurposing Metformin for Vascular Disease.

Triggle C, Marei I, Ye K, Ding H, Anderson T, Hollenberg M Curr Med Chem. 2022; 30(35):3955-3978.

PMID: 35909294 PMC: 10286558. DOI: 10.2174/0929867329666220729154615.

Metformin Corrects Glucose Metabolism Reprogramming and NLRP3 Inflammasome-Induced Pyroptosis via Inhibiting the TLR4/NF-B/PFKFB3 Signaling in Trophoblasts: Implication for a Potential Therapy of Preeclampsia.

Zhang Y, Liu W, Zhong Y, Li Q, Wu M, Yang L Oxid Med Cell Longev. 2021; 2021:1806344.

PMID: 34804360 PMC: 8601820. DOI: 10.1155/2021/1806344.

References

Fadini G, Miorin M, Facco M, Bonamico S, Baesso I, Grego F . Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005; 45(9):1449-57. DOI: 10.1016/j.jacc.2004.11.067. View

Johnson J, Majumdar S, Simpson S, Toth E . Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002; 25(12):2244-8. DOI: 10.2337/diacare.25.12.2244. View

Hill J, Zalos G, Halcox J, Schenke W, Waclawiw M, Quyyumi A . Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348(7):593-600. DOI: 10.1056/NEJMoa022287. View

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-74. PMC: 209533. DOI: 10.1172/JCI13505. View

Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A . Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353(10):999-1007. DOI: 10.1056/NEJMoa043814. View

Numaguchi Y, Sone T, Okumura K, Ishii M, Morita Y, Kubota R . The impact of the capability of circulating progenitor cell to differentiate on myocardial salvage in patients with primary acute myocardial infarction. Circulation. 2006; 114(1 Suppl):I114-9. DOI: 10.1161/CIRCULATIONAHA.105.000588. View

. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View

. Standards of medical care in diabetes--2008. Diabetes Care. 2008; 31 Suppl 1:S12-54. DOI: 10.2337/dc08-S012. View

Haendeler J, Dimmeler S . Inseparably tied: functional and antioxidative capacity of endothelial progenitor cells. Circ Res. 2006; 98(2):157-8. DOI: 10.1161/01.RES.0000204552.28409.a2. View

10.

Kim W, Jeong M, Cho S, Yun J, Chae H, Ahn Y . Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J. 2006; 70(8):1052-7. DOI: 10.1253/circj.70.1052. View

11.

Ukinc K, Eminagaoglu S, Ersoz H, Erem C, Karahan C, Hacihasanoglu A . A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine. 2009; 36(3):425-32. DOI: 10.1007/s12020-009-9236-5. View

12.

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

13.

Kao J, Tobis J, McClelland R, Heaton M, Davis B, Holmes Jr D . Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol. 2004; 93(11):1347-50, A5. DOI: 10.1016/j.amjcard.2004.02.028. View

14.

Kahler K, Rajan M, Rhoads G, Safford M, Demissie K, Lu S . Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care. 2007; 30(7):1689-93. DOI: 10.2337/dc06-2272. View

15.

Thum T, Fraccarollo D, Schultheiss M, Froese S, Galuppo P, Widder J . Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes. 2007; 56(3):666-74. DOI: 10.2337/db06-0699. View

16.

Rafii S, Lyden D . Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003; 9(6):702-12. DOI: 10.1038/nm0603-702. View

17.

. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20(7):1183-97. DOI: 10.2337/diacare.20.7.1183. View

18.

Chen Y, Lin S, Lin F, Wu T, Tsao C, Huang P . High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes. 2007; 56(6):1559-68. DOI: 10.2337/db06-1103. View

19.

Fadini G, Sartore S, Agostini C, Avogaro A . Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care. 2007; 30(5):1305-13. DOI: 10.2337/dc06-2305. View

20.

Macfarlane D, Paterson K, Fisher M . Oral antidiabetic agents as cardiovascular drugs. Diabetes Obes Metab. 2007; 9(1):23-30. DOI: 10.1111/j.1463-1326.2006.00592.x. View